Skip to main content
. Author manuscript; available in PMC: 2007 Sep 21.
Published in final edited form as: Pharmacogenet Genomics. 2007 Jan;17(1):37–45. doi: 10.1097/01.fpc.0000236325.73186.2c

Figure 6.

Figure 6

COS-1 cells were transfected with NAT2*411T (top) or NAT2*4 (bottom) 24 h before treatment with 5 μM MG-132 (open circles), 5 μM lactacystin (LAC, solid circles), or DMSO as a negative vehicle control (open squares). Cells were harvested at different time points after the treatment, and the cell lysates were tested for SMZ NAT2 catalytic activity. Each data point represents the mean ± standard error of three independent treatments.